Genericisation in cost-effectiveness analysis of cystic fibrosis medicines.
Lancet
; 403(10444): 2591-2592, 2024 Jun 15.
Article
in En
| MEDLINE
| ID: mdl-38879249
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drugs, Generic
/
Cost-Benefit Analysis
/
Cystic Fibrosis
Limits:
Humans
Language:
En
Journal:
Lancet
Year:
2024
Document type:
Article
Affiliation country:
United kingdom